Anavex Comments on President Obama’s National Plan to Fight Alzheimer’s Disease

Vancouver, BC — May 30, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on President Obama’s National Alzheimer’s Plan, which was unveiled earlier this month.  It is part of the National Alzheimer’s Project Act (NAPA), which was signed into law in January 2011. NAPA is the first-ever national plan to address Alzheimer’s disease. …

Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer’s Disease, at Japan Neuroscience Society Special Symposium

Hoboken, NJ — September 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer’s disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society. The symposium is being held inYokohama,Japan from September…

Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease

Hoboken, NJ — July 26, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.” Neuroprotective, anti-amnesic, anti-depressive…

Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology

Hoboken, NJ — July 25, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran derivative ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model…

Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease

Hoboken, NJ — July 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in…

Anavex Raises $1.575 million

Hoboken, NJ — July 11, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to announce that it has raised $1,575,000 through the exercise of warrants.  Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease, to advance other compounds in…